Cavinton, 5 mg/ml 10 ml 10 pcs

Cavinton is a drug that improves cerebral blood flow, cerebral metabolism and rheological properties of blood.
It has cerebroprotective effect. It reduces severity of damaging cytotoxic reactions caused by stimulating amino acids; inhibits functional activity of both cellular transmembrane sodium and calcium channels and NMDA and AMPA receptors. Potentiates neuroprotective effect of adenosine.

Stimulates brain metabolism, increases absorption and assimilation of glucose and oxygen by brain. Stimulates the transport of glucose through the GEB, shifts glucose metabolism in an energetically more favorable aerobic direction. Selectively inhibits Ca²⁺-calmodulin-dependent cGMP-phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissues, as well as ATP concentration and ATP/AMP ratio. It stimulates cerebral metabolism of noradrenaline and serotonin, stimulates the ascending noradrenergic system and has an antioxidant effect.

The drug selectively increases cerebral blood flow: increases cerebral fraction of minute volume; decreases resistance of cerebral vessels without affecting parameters of total blood circulation (BP, minute volume, HR, RPS).

It does not cause the phenomenon of “stealing”; on the contrary, its use primarily increases the blood supply to the ischemic, but still viable area with low perfusion – the phenomenon of “reverse stealing”.

It improves the tolerance of hypoxia by brain cells by promoting the transport of oxygen to the tissues due to a decrease in the affinity of red blood cells for it.

The drug improves microcirculation in the brain, inhibits platelet aggregation, reduces abnormally high blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Indications

In neurology – acute and chronic cerebrovascular insufficiency (transient ischemia, progressive stroke, conditions after stroke, vascular dementia, atherosclerosis of brain vessels, post-traumatic and hypertensive encephalopathy, vertebrobasilar insufficiency); psychiatric and neurological disorders in patients with cerebrovascular insufficiency (including memory impairment, dizziness, headache, aphasia, apraxia, movement disorders.including memory impairment, dizziness, headache, aphasia, apraxia, movement disorders).

In ophthalmology – vascular eye diseases (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or yellow spot, arterial and venous thrombosis or embolism, secondary glaucoma).

In ENT practice – hearing loss (vascular, toxic or age-related), Meniere’s disease, cochleovestibular neuritis, tinnitus, vertigo (labyrinthine origin); vasovesthetal manifestations of menopausal syndrome.

Active ingredient

Composition

1 ml contains vinpocetine 5 mg. 1 ampoule – 50 mg.

Auxiliary substances:

ascorbic acid,

sodium disulfite,

tartaric acid,

benzyl alcohol,

sorbitol,

d/i water.

How to take, the dosage

The drug is intended for intravenous drip infusion. Administer slowly; the infusion rate should not exceed 80 drops/min.

The drug must not be administered by injection and IV without dilution.

Physiological solution or solutions containing dextrose (Salsol, Ringer, Rindex, Reomacrodex) can be used to prepare infusion. Infusion solution with Cavinton should be used in the first 3 hours after preparation.

The usual initial daily dose is 20-25 mg in 500 ml of infusion solution. Depending on tolerance, within 2-3 days the dose may be increased to no more than 1 mg/kg/day. The average duration of treatment is 10-14 days.

The average daily dose in case of body weight of 70 kg is 50 mg (in 500 ml of infusion solution).

Dose adjustment is not required in case of liver and kidney diseases.

At the end of the course of IV therapy it is recommended to continue treatment with tablets Kavinton Forte (1 tablet 3 times/day) or Kavinton (2 tablets 3 times/day).

Special Instructions

Cavinton does not have hepato- and nephrotoxic effects, so when prescribing the drug to patients with liver and kidney disease does not require dosing regimen adjustment.
Pediatric use
It is not recommended to prescribe the drug to children under 18 years of age due to lack of experience in using Cavinton in this category of patients.

Contraindications

Side effects

Cardiovascular system disorders: aggravation of existing arrhythmias is possible.

Digestive system disorders: nausea, heartburn, dry mouth.

CNS disorders: headache, dizziness, insomnia, weakness.

Allergic reactions: skin rash, urticaria.

Skin reactions: skin hyperemia.

Overdose

The data on overdose of Cavinton are currently limited.

Treatment: conduct symptomatic therapy.

Pregnancy use

The drug is contraindicated in pregnancy and lactation.

Similarities